Search

Corvus Pharmaceuticals Inc

Open

14.37 1.63

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

14.07

Max

14.4

Schlüsselkennzahlen

By Trading Economics

Einkommen

-4.3M

-18M

EPS

-0.19

Angestellte

37

EBITDA

-5.3M

-17M

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

+107.75% upside

Dividenden

By Acuity

Nächstes Ergebnis

3. Nov. 2026

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

57M

1.2B

Vorheriger Eröffnungskurs

12.74

Vorheriger Schlusskurs

14.37

Corvus Pharmaceuticals Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

2. Sept. 2026, 23:56 UTC

Fidelity National Financial shares are higher in after-market trading, recovering from earlier losses but remain below the 20-day moving average.

2. Sept. 2026, 23:56 UTC

MGM Resorts International shares are higher in after-market trading, supported by a broader market response to weaker ADP private payrolls data.

2. Sept. 2026, 23:56 UTC

News

Entergy Corp settled its 2025 forward sale agreements, delivering over 11 million shares for $913 million. Shares are higher in after-market trading.

2. Sept. 2026, 23:56 UTC

Correlated Moves

Equinix Inc. shares are higher in after-market trading, supported by a weaker ADP payrolls report indicating lower job growth than expected.

2. Sept. 2026, 23:56 UTC

Biogen Inc shares are higher in after-market trading, despite no specific news. Broader market dynamics may be influenced by weaker ADP payrolls data.

2. Sept. 2026, 23:56 UTC

Exelixis Inc shares are higher in after-market trading, though no specific news was identified. The broader market reacted to weaker ADP payroll data.

2. Sept. 2026, 23:56 UTC

APA Corp. shares are trading roughly flat in after-market hours. Market sentiment is influenced by weaker ADP payroll data, easing rate hike concerns.

2. Sept. 2026, 23:56 UTC

Abbott Laboratories shares are lower in after-market hours, reflecting a decline since Wednesday's close amid weaker-than-expected job growth reported by ADP.

2. Sept. 2026, 23:56 UTC

Union Pacific Corp shares are lower in after-market hours amid volatility, following disappointing ADP payroll data that may affect Federal Reserve interest rate expectations.

2. Sept. 2026, 23:56 UTC

T Rowe Price Group Inc shares are trading lower in after-market hours following a volatile session amid reactions to weaker-than-expected ADP payroll data.

2. Sept. 2026, 23:52 UTC

Mexico's inflation rate expected to stabilize around 3% amid cautious market sentiment and external risks ahead of September release.

2. Sept. 2026, 23:52 UTC

Mexican Inflation Data Release on September 9, Amid Cautious Optimism and Ongoing Economic Risks.

2. Sept. 2026, 23:52 UTC

Australia's Westpac Consumer Confidence Index set for release on September 8, 2026, amid mixed sentiments and rising economic pressures.

2. Sept. 2026, 23:52 UTC

US ISM Services PMI Expected to Rise Slightly to 54.3, Indicating Continued Expansion Amid Economic Challenges

2. Sept. 2026, 23:52 UTC

Australia's Westpac Consumer Confidence Index set for release amid cautious optimism and external inflation risks on September 8, 2026.

2. Sept. 2026, 23:51 UTC

Dorian LPG Ltd shares are lower in after-market hours, following five consecutive sessions of gains. The decline coincides with a weaker ADP payrolls report.

2. Sept. 2026, 23:51 UTC

Hackett Group Inc shares are lower in after-market hours, continuing a decline since Wednesday's close and trading below their 20-day moving average.

2. Sept. 2026, 23:51 UTC

Champion Homes Inc is rising in after-market trading, supported by gains in the Homebuilding sub-sector. The asset has recovered from earlier session lows.

2. Sept. 2026, 23:51 UTC

Essential Properties Realty Trust shares are higher in after-market trading. Broader market trends and recent economic data may be influencing this movement.

2. Sept. 2026, 23:51 UTC

ETF Constituents
Macro News

State Street Financial Select Sector SPDR ETF rises in after-market hours as weaker job growth eases Fed rate hike concerns and key holdings perform well.

2. Sept. 2026, 23:51 UTC

IQVIA Holdings Inc shares rose in after-market trading, continuing upward momentum amid a broader macroeconomic backdrop following the ADP payrolls report.

2. Sept. 2026, 23:51 UTC

Correlated Moves

Republic Bancorp Inc shares declined in after-hours trading, reflecting broader financial sector weakness amid disappointing job creation data from the ADP report.

2. Sept. 2026, 23:51 UTC

South Plains Financial Inc is trading lower in after-market hours, continuing a trend seen during the regular session amid broader market weakness following a disappointing ADP report.

2. Sept. 2026, 23:51 UTC

Keysight Technologies Inc shares are lower in after-market hours, continuing a decline from earlier in the session amid a challenging trading environment.

2. Sept. 2026, 23:51 UTC

Sylvamo Corp shares are lower in after-market trading, continuing a decline from earlier in the session amid broader market weakness following the ADP payrolls report.

2. Sept. 2026, 23:51 UTC

Maximus Inc shares are higher in after-market trading, rebounding from earlier lows. Weaker ADP payroll data may ease concerns over aggressive Fed rate hikes.

2. Sept. 2026, 23:51 UTC

New York Times Co shares are higher in after-market trading, supported by a solid market backdrop and recent ADP payrolls report indicating slower job growth.

2. Sept. 2026, 23:51 UTC

Best Buy Co Inc shares are higher in after-market trading, supported by gains in the Computer & Electronics Retail sub-sector and maintaining a notable high.

2. Sept. 2026, 23:51 UTC

U.S. equity indices rebound amid weak job growth and rising oil prices, while geopolitical tensions and climbing bond yields raise inflation concerns.

2. Sept. 2026, 23:51 UTC

Asian equity markets decline amid U.S.-Iran tensions and rising bond yields, while U.S. stocks rebound ahead of key jobs data impacting Fed rate outlook.

Peer-Vergleich

Kursveränderung

Corvus Pharmaceuticals Inc Prognose

Kursziel

By TipRanks

107.75% Vorteil

12-Monats-Prognose

Durchschnitt 29.5 USD  107.75%

Hoch 33 USD

Tief 27 USD

Basierend auf 4 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Corvus Pharmaceuticals Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

4 ratings

4

Buy

0

Halten

0

Sell

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.
help-icon Live chat